NCT04396002 Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
| NCT ID | NCT04396002 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alabama at Birmingham |
| Condition | Primary Open Angle Glaucoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2019-06-01 |
| Primary Completion | 2026-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2019-06-01 with a primary completion date of 2026-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Mobility refers to a person's purposeful movement through the environment from one place to another and can be conceptualized as a continuum from bed bound (immobility) on one extreme to making excursions to distant locations on the other extreme. Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy that can lead to gradual loss of vision in the peripheral field and central vision. Older adults with POAG have an increased risk for motor vehicle collisions and falls. Moreover, existing studies suggest that patients with POAG exhibit more postural sway while standing as measured by a balance platform and also tend to walk more slowly than those who are normally sighted and free of ocular disease. While these disturbances likely influence mobility, there has been little research directly assessing the impact of POAG on mobility. This study will assess the impact of POAG on life space (one aspect of mobility) and will determine whether difficulties with life space are associated with difficulties experienced under conditions of dim lighting.
Eligibility Criteria
Inclusion Criteria (Patients): * Participants that are enrolled in the Early Detection of Glaucoma Progression using a Novel Individualized Approach (IRB-300000301) or in the African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the Lamina Cribrosa in Progression (IRB-161115004). Exclusion Criteria (Patients): * Not being enrolled in one of the following two NIH-funded studies: 1. African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the lamina cribrosa in progression (EY026574) or 2. Early detection of glaucoma progression using a novel individualized approach (EY025756) Inclusion Criteria (Controls): * No diagnosis of eye disease Exclusion Criteria (Controls): * Cognitive impairment that would preclude ability to take the tests
Contact & Investigator
Lyne Racette, PhD
PRINCIPAL INVESTIGATOR
University of Alabama at Birmingham
Frequently Asked Questions
Who can join the NCT04396002 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Primary Open Angle Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04396002 currently recruiting?
Yes, NCT04396002 is actively recruiting participants. Contact the research team at lracette@uabmc.edu for enrollment information.
Where is the NCT04396002 trial being conducted?
This trial is being conducted at Birmingham, United States.
Who is sponsoring the NCT04396002 clinical trial?
NCT04396002 is sponsored by University of Alabama at Birmingham. The principal investigator is Lyne Racette, PhD at University of Alabama at Birmingham. The trial plans to enroll 100 participants.